Braskem (BAK) Cash & Equivalents (2009 - 2025)

Braskem (BAK) has reported Cash & Equivalents for 17 consecutive years, with $1.9 billion the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 24.47% year-over-year to $1.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 billion (down 24.47% YoY) and the FY2025 annual result came in at $1.9 billion, down 24.47% from the prior year.
• Cash & Equivalents climbed to $1.9 billion in Q4 2025 per BAK's latest filing, from $1.9 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for BAK reached as high as $2.9 billion in Q4 2023 and fell as low as $1.6 billion in Q4 2021.
• A 5-year average of $2.3 billion and a median of $2.3 billion in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents tumbled 39.39% — and 2022, when it soared 52.26%.
• Year by year, Cash & Equivalents stood at $1.6 billion in 2021, then surged by 52.26% to $2.4 billion in 2022, then grew by 20.94% to $2.9 billion in 2023, then slipped by 10.02% to $2.6 billion in 2024, then dropped by 24.47% to $1.9 billion in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.9 billion, $1.9 billion, and $2.6 billion for Q4 2025, Q1 2025, and Q4 2024 respectively.